Iovance Biotherapeutics (NASDAQ: IOVA) revenue
Iovance Biotherapeutics reported revenue of $263.5m for fiscal 2025, 60.6% more than in fiscal 2024 ($164.1m).
Iovance Biotherapeutics has grown its revenue for 2 years in a row, and fiscal 2025 is the highest of its 6 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $263.5m | +60.6% | −$403.4m | −153.1% |
| 2024 | $164.1m | +13,699.0% | −$395.3m | −240.9% |
| 2023 | $1.2m | — | −$460.6m | −38,735.0% |
| 2018 | $0.0m | — | −$128.3m | — |
| 2017 | $0.0m | — | −$92.9m | — |
| 2016 | $0.0m | — | −$53.6m | — |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Iovance Biotherapeutics revenue compared with its sector
By revenue for its latest fiscal year, Iovance Biotherapeutics ranks 230th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Iovance Biotherapeutics, 60.6%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 228th | Viemed Healthcare | $270.3m | 20.5% |
| 229th | Ligand Pharmaceuticals | $268.1m | 60.4% |
| 230th | Iovance Biotherapeutics | $263.5m | 60.6% |
| 231st | Arvinas | $262.6m | −0.3% |
| 232nd | Schrodinger | $255.9m | 23.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Iovance Biotherapeutics
- How much revenue did Iovance Biotherapeutics make in fiscal 2025?
- Iovance Biotherapeutics reported revenue of $263.5m for fiscal 2025, compared with $164.1m in fiscal 2024.
- What was the best year for revenue at Iovance Biotherapeutics?
- Of its last 6 fiscal years, fiscal 2025, with $263.5m.
- Where does Iovance Biotherapeutics rank in its sector by revenue?
- It ranks 230th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Iovance Biotherapeutics come from?
- From the annual report (Form 10-K) that Iovance Biotherapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Iovance Biotherapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2018 · 2017 · 2016. More on Iovance Biotherapeutics: the Iovance Biotherapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.